Medtronic (NYSE:MDT) announced two new milestones for its Affera Sphere-360 catheter for pulsed field ablation (PFA) ...
Sphere-9 demonstrated 73.8% freedom from AFib vs. only 65.8% observed in the control arm. AFib is one of the most common and undertreated heart rhythm disorders, affecting more than 60 million people ...
Medtronic (NYSE:MDT) said a clinical study for its Affera Mapping and Ablation System with Sphere-9 Catheter for the treatment of persistent atrial fibrillation has met its endpoints for safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results